drugset / Trial / NCT07600151
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Phase 1/2
Not yet recruiting
220 enrolled
University Medical Center Hamburg-Eppendorf
AbbVie · collabSanofi · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2036-09-30
- Completion
- 2036-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etentamig | Monoclonal antibody | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Isatuximab | Monoclonal antibody | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |